These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 24793055)

  • 1. Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its SMRT, NcoR and BCOR corepressors: the quest for a consensus dynamic pharmacophore.
    Granadino-Roldán JM; Obiol-Pardo C; Pinto M; Garzón A; Rubio-Martínez J
    J Mol Graph Model; 2014 May; 50():142-51. PubMed ID: 24793055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
    Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.
    Ghetu AF; Corcoran CM; Cerchietti L; Bardwell VJ; Melnick A; Privé GG
    Mol Cell; 2008 Feb; 29(3):384-91. PubMed ID: 18280243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
    Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
    Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
    Ahmad KF; Melnick A; Lax S; Bouchard D; Liu J; Kiang CL; Mayer S; Takahashi S; Licht JD; Privé GG
    Mol Cell; 2003 Dec; 12(6):1551-64. PubMed ID: 14690607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
    Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
    Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of Apt48 inhibition of the BCL6 BTB domain.
    Zacharchenko T; Kalverda AP; Wright SC
    Structure; 2022 Mar; 30(3):396-407.e3. PubMed ID: 34774129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.
    Evans SE; Goult BT; Fairall L; Jamieson AG; Ko Ferrigno P; Ford R; Schwabe JW; Wagner SD
    PLoS One; 2014; 9(3):e90889. PubMed ID: 24595451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Backbone resonance assignment of the BCL6-BTB/POZ domain.
    Lin LY; Evans SE; Fairall L; Schwabe JWR; Wagner SD; Muskett FW
    Biomol NMR Assign; 2018 Apr; 12(1):47-50. PubMed ID: 28929458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation inactivates the transcriptional repressor BCL6.
    Bereshchenko OR; Gu W; Dalla-Favera R
    Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-androgen effects of the pyrethroid pesticide cypermethrin on interactions of androgen receptor with corepressors.
    Pan C; Wang Q; Liu YP; Xu LF; Li YF; Hu JX; Jiang M; Zhang JP; Zhang MR; Yu HM; Zhou JL; Zhou XL; Xu LC
    Toxicology; 2013 Sep; 311(3):178-83. PubMed ID: 23831764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design.
    Yasui T; Yamamoto T; Sakai N; Asano K; Takai T; Yoshitomi Y; Davis M; Takagi T; Sakamoto K; Sogabe S; Kamada Y; Lane W; Snell G; Iwata M; Goto M; Inooka H; Sakamoto JI; Nakada Y; Imaeda Y
    Bioorg Med Chem; 2017 Sep; 25(17):4876-4886. PubMed ID: 28760529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR assignments of SPOC domain of the human transcriptional corepressor SHARP in complex with a C-terminal SMRT peptide.
    Mikami S; Kanaba T; Ito Y; Mishima M
    Biomol NMR Assign; 2013 Oct; 7(2):267-70. PubMed ID: 22987228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAC1, a POZ/BTB protein that functions as a corepressor.
    Korutla L; Wang P; Jackson TG; Mackler SA
    Neurochem Int; 2009; 54(3-4):245-52. PubMed ID: 19121354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the Recruitment of Class IIa Histone Deacetylases (HDACs) to the SMRT/NCoR Transcriptional Repression Complex.
    Hudson GM; Watson PJ; Fairall L; Jamieson AG; Schwabe JWR
    J Biol Chem; 2015 Jul; 290(29):18237-18244. PubMed ID: 26055705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
    Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
    Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.
    Barish GD; Yu RT; Karunasiri MS; Becerra D; Kim J; Tseng TW; Tai LJ; Leblanc M; Diehl C; Cerchietti L; Miller YI; Witztum JL; Melnick AM; Dent AL; Tangirala RK; Evans RM
    Cell Metab; 2012 Apr; 15(4):554-62. PubMed ID: 22465074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insights into the recruitment of SMRT by the corepressor SHARP under phosphorylative regulation.
    Mikami S; Kanaba T; Takizawa N; Kobayashi A; Maesaki R; Fujiwara T; Ito Y; Mishima M
    Structure; 2014 Jan; 22(1):35-46. PubMed ID: 24268649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
    Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
    J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.
    Cerchietti LC; Ghetu AF; Zhu X; Da Silva GF; Zhong S; Matthews M; Bunting KL; Polo JM; Farès C; Arrowsmith CH; Yang SN; Garcia M; Coop A; Mackerell AD; Privé GG; Melnick A
    Cancer Cell; 2010 Apr; 17(4):400-11. PubMed ID: 20385364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.